Skip to Main Content

Abstracts

Order by

B01 – Immune Checkpoint Markers in Pulmonary Large Cell Neuroendocrine Carcinomas

Published in 2017 Listed under Basic Science

Abdel Karim

Abstract ID: 300

B02 – The HNV Pancreatic Neuroendocrine Tumor Model

Published in 2017 Listed under Basic Science, Poster

Chamberlain

Abstract ID: 273

pdf Download Poster (9.58 MB)

B03 – Potentiating mTOR’s Antineoplastic Effects with Rovalpituzumab Tesirate in Neuroendocrine Tumors

Published in 2017 Listed under Basic Science

Chauhan

Abstract ID: 251

B04 – Oncogenic Signaling in the PNETs of Multiple Endocrine Neoplasia Type 1 is Epigenetically Regulated by the LncRNA Meg3

Published in 2017 Listed under Basic Science

Iyer

Abstract ID: 225

B05 – Developing Model Systems of Neuroendocrine Tumors: Cell Lines and Patient-Derived Xenograft (PDX) Tumors

Published in 2017 Listed under Basic Science

Kaemmer

Abstract ID: 276

B06 – Gene Expression Changes in Small Bowel Neuroendocrine Tumors Associated with Progression to Metastases

Published in 2017 Listed under Basic Science, Poster

Keck

Abstract ID: 210

pdf Download Poster (1020 KB)

B07 – Transcriptional Alterations in Hereditary and Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors According to Genotype

Published in 2017 Listed under Basic Science

Keutgen

Abstract ID: 207

B08 – Somatostatin Receptor Imaging and Therapy in MEN1-Driven Murine Pancreatic Neuroendocrine Tumors

Published in 2017 Listed under Basic Science

Li

Abstract ID: 301

B09 – Molecular Imaging of High-Grade Neuroendocrine Tumors Using Novel Peptide-Receptor Targeted Radiopharmaceuticals

Published in 2017 Listed under Basic Science

Liu

Abstract ID: 267

B10 – Enriched Immune Cell Activities in the Tumor Microenviroments of Metastatic Pancreatic Neuroendocrine Tumors

Published in 2017 Listed under Basic Science

Moore

Abstract ID: 302

B11 – Efficacy of mTOR Inhibition in Pulmonary Large Cell Neuroendocrine Carcinomas (LCNEC)

Published in 2017 Listed under Basic Science

Orr-Asman

Abstract ID: 278

B12 – Evaluating Transcription Factor Networks as Targets for the Treatment of Neuroendocrine Tumors

Published in 2017 Listed under Basic Science

Pozo

Abstract ID: 269

B13 – Isolation and Characterization of Small Bowel Neuroendocrine Tumor Cell Line

Published in 2017 Listed under Basic Science

Rodman

Abstract ID: 310

B14 – ONECUT2: A Targetable Master Regulator of Progression to Neuroendocrine Differentiation from Prostate Adenocarcinoma

Published in 2017 Listed under Basic Science

Rotinen

Abstract ID: 272

B15 – Sensitizing Hypoxic Small Cell Lung Cancer Cells to Radiation and Hydrogen Peroxide-Producing Agents Using CuATSM

Published in 2017 Listed under Basic Science

Sciegienka

Abstract ID: 282

B16 – RABL6A-Dependent Regulation of c-Myc Expression and Activity is Essential for Cell Cycle Progression and Survival of Pancreatic Neuroendocrine Tumor Cells

Published in 2017 Listed under Basic Science, Poster

Abstract ID: 298

Author: Sheehy

pdf Download Poster (1.26 MB)

B17 – A New Critical Regulator of Akt-mTOR Signaling in Pancreatic Neuroendocrine Tumor Cells

Published in 2017 Listed under Basic Science, Poster

Umesalma

Abstract ID: 289

pdf Download Poster (1.15 MB)

B18 – Testicular Receptor-4 (TR4): Novel Predictive Biomarker for Disease Related Survival in pNETs

Published in 2017 Listed under Basic Science

Zhang

Abstract ID: 304

B19 – DAXX Mutation is Associated with Shorter Hepatic Progression Free Survival After Hepatic Artery Embolization of Neuroendocrine Liver Metastases

Published in 2017 Listed under Basic Science

Ziv

Abstract ID: 281

B20 – Immune Checkpoint Inhibitors in Progressive Neuroendocrine Tumors

Published in 2017 Listed under Applied Basic Science, Basic Science

Chauhan

Abstract ID: 254

B21 – Role of 92 Gene Cancer Classifier Assay in Neuroendocrine Tumor of Unknown Primary

Published in 2017 Listed under Applied Basic Science, Basic Science

Chauhan

Abstract ID: 257

B22 – Molecular Classification of Neuroendocrine Tumors: Clinical Experience with the 92-gene Assay in >24,000 Cases

Published in 2017 Listed under Applied Basic Science, Basic Science, Poster

Hendifar

Abstract ID: 224

pdf Download Poster (532 KB)

B23 – Diagnostic Utility of SATB2 in Determining the Site of Origin of Well-Differentiated Neuroendocrine Tumors

Published in 2017 Listed under Applied Basic Science, Basic Science

Mohanty

Abstract ID: 305

B24 – Activation of Alternative Lengthening of Telomeres (ALT) in Primary Pancreatic Neuroendocrine Tumors Serves as Both a Prognostic Biomarker and Potential Therapeutic Target

Published in 2017 Listed under Applied Basic Science, Basic Science

Rizzo

Abstract ID: 233

C01 – Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Published in 2017 Listed under Clinical, Poster

Aggarwal

Abstract ID: 229

pdf Download Poster (795 KB)

C02 – Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Published in 2017 Listed under Clinical, Poster

Al-Toubah

Abstract ID: 241

pdf Download Poster (450 KB)

C03 – Systematic Literature Review of Octreotide's Antitumor Effects in Neuroendocrine Tumors

Published in 2017 Listed under Clinical, Poster

Barrows

Abstract ID: 221

pdf Download Poster (233 KB)

C04 – Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Chan

Abstract ID: 290

C05 – Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study

Published in 2017 Listed under Clinical, Poster

Dillon

Abstract ID: 255

pdf Download Poster (728 KB)

C06 – An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)

Published in 2017 Listed under Clinical

Duchateau

Abstract ID: 222

C07 – 5-Hydroxyindoleacetic Acid (5-HIAA) and Chromogranin A (CgA) as Biomarkers Secreted by Neuroendocrine Tumors (NETs): a Pooled Analysis of the ELECT and CLARINET Studies

Published in 2017 Listed under Clinical

Fisher, Jr

Abstract ID: 232

C08 – Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs)

Published in 2017 Listed under Clinical, Poster

Gutierrez

Abstract ID: 249

pdf Download Poster (289 KB)

C09 – Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period

Published in 2017 Listed under Clinical, Poster

Hörsch

Abstract ID: 214

pdf Download Poster (724 KB)

C10 – Predictors of Somatostatin Analogs (SSA) Dose Escalations (DEs) Above Recommended Dosing Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treated at a Tertiary Referral Center

Published in 2017 Listed under Clinical, Poster

Jalbert

Abstract ID: 277

pdf Download Poster (655 KB)

C11 – Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease

Published in 2017 Listed under Clinical, Poster

Lapuerta

Abstract ID: 212

pdf Download Poster (263 KB)

C12 – Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of DP1038, an Intranasal Formulation of Octreotide Acetate, in Healthy Volunteers

Published in 2017 Listed under Clinical, Poster

Lavisetti

Abstract ID: 204

pdf Download Poster (758 KB)

C13 – Use of Somatostatin Analog Therapy in Patients with Advanced Pheochromocytoma/Paraganglioma and Somatostatin-Receptor Avid Disease

Published in 2017 Listed under Clinical, Poster

Narayan

Abstract ID: 228

pdf (727 KB) pdf Download Poster (1.64 MB)

C14 – Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial

Published in 2017 Listed under Clinical, Poster

Pavel

Abstract ID: 213

pdf Download Poster (727 KB)

C15 – Safety and Tolerability of Lanreotide Autogel/Depot in Patients with Neuroendocrine Tumors: Pooled Analysis of Clinical Studies

Published in 2017 Listed under Clinical

Phan

Abstract ID: 226

C16 – Elevated Levels of 5-HIAA and CgA in Patients with Pancreatic Neuroendocrine Tumors (PanNETs): Analyses from the CLARINET Study

Published in 2017 Listed under Clinical

Phan

Abstract ID: 226

C17 – Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study

Published in 2017 Listed under Clinical

Pommier

Abstract ID: 223

C18 – Pharmacist-Led Development of an Adverse Event (AE) Management Algorithm for the Proactive Monitoring of Patients with Neuroendocrine Tumours (NETs) on Everolimus

Published in 2017 Listed under Clinical

Thawer

Abstract ID: 299

C19 – Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Published in 2017 Listed under Clinical, Poster

Weickert

Abstract ID: 253

pdf Download Poster (727 KB)

C20 – Impact of Adjuvant Chemotherapy in Non-Metastatic Node Positive Bronchial Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Westin

Abstract ID: 236

C21 – Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot

Published in 2017 Listed under Clinical

Wolin

Abstract ID: 238

C22 – Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: the CLARINET Extension Study

Published in 2017 Listed under Clinical, Poster

Wolin

Abstract ID: 262

pdf Download Poster (842 KB)

C23 – The Predictive Quotient Index Comprising Gene Cluster Analysis and Grading is Specifically Predictive of PRRT Efficacy

Published in 2017 Listed under Clinical

Bodei

Abstract ID: 287

C24 – Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors

Published in 2017 Listed under Clinical, Poster

Chan

Abstract ID: 256

pdf (381 KB) pdf Download Poster (381 KB)

C25 – MIBG Avidity and Progression-Free Survival in Patients with Metastatic Pheochromocytoma are not Dependent on Germline SDHx Mutation Status

Published in 2017 Listed under Clinical

Fishbein

Abstract ID: 261

C26 – Education and Preparation for Nuclear Medicine Procedures in Neuroendocrine Tumor Patients

Published in 2017 Listed under Clinical, Poster

Hedrick

Abstract ID: 279

pdf Download Poster (1.06 MB)

C27 – Synthesis and Characterization of a 68Ga/NIR Labeled Peptide for Somatostatin Receptor Targeting

Published in 2017 Listed under Clinical, Poster

Hernandez-Vargas

Abstract ID: 237

pdf Download Poster (1010 KB)

C28 – AZEDRA® (iobenguane I 131) in Patients with Malignant and/or Recurrent Pheochromocytoma/ Paraganglioma (PPGL): Final Results of a Multi-Center, Open-Label, Pivotal Phase 2b Study

Published in 2017 Listed under Clinical

Jiminez

Abstract ID: 240

C29 – Safety and Accuracy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Children and Young Adults with Solid Tumors

Published in 2017 Listed under Clinical

O'Dorisio

Abstract ID: 303

C30 – Potential for Increasing Tumor Uptake of Radiolabeled MIBG and/or DOTATOC in Patients with Mid-Gut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor

Published in 2017 Listed under Clinical, Poster

Pollard

Abstract ID: 209

pdf Download Poster (518 KB)

C31 – Theranostic Trial of Well Differentiated Neuroendocrine Tumors (NETs) with 68Ga-OPS201 and 177Lu-OPS201

Published in 2017 Listed under Clinical

Reidy-Lagunes

Abstract ID: 263

C32 – Feasibility & Safety of Integrated CapTemY90 for Liver-Dominant G2 NETS

Published in 2017 Listed under Clinical, Poster

Soulen

Abstract ID: 227

pdf Download Poster (869 KB)

C33 – QOL Improvements in NETTER-1 Phase III Trial in Patients with Progressive Midgut Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Strosberg

Abstract ID: 205

C34 – Computerized Mutation Prediction Models May be Used to Determine VHL-Associated PNETs Aggressiveness

Published in 2017 Listed under Clinical

Tirosh

Abstract ID: 247

C35 – Potential Reduction in Radiation Exposure and in Risk for Malignancy by Using VHL Genotype-Directed Protocol for the Surveillance of PNETs in Patients with Von Hippel-Lindau Disease

Published in 2017 Listed under Clinical

Tirosh

Abstract ID: 248

C36 – PFS and OS After Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lu[Dota°,Tyr³]octreotate in Patients with GastroEnteroPancreatic or Bronchial NeuroEndocrine Tumours (GEP-NETs) – The Rotterdam Cohort

Published in 2017 Listed under Clinical

van der Zwan

Abstract ID: 284

C37 – Trans-Anal Minimally Invasive Surgery (TAMIS) for Completion Excision of Localized Well-Differentiated Rectal Neuroendocrine Tumours

Published in 2017 Listed under Clinical, Poster

Chan

Abstract ID: 274

pdf Download Poster (545 KB)

C38 – Changes in Catecholamine and Metanephrine Levels and 24–Hour Ambulatory Blood Pressure Parameters Before and After Catecholamine-Secreting Neuroendocrine Tumor Resection

Published in 2017 Listed under Clinical, Poster

Cohen MD, MSCE

Abstract ID: 246

pdf Download Poster (294 KB)

C39 – RNA based In Situ Hybridization for Polyoma Virus is Helpful in Differentiating Merkel Cell Carcinoma from Other High Grade Neuroendocrine Carcinomas

Published in 2017 Listed under Clinical

Dhall

Abstract ID: 307

C40 – The Clinical Utility of Blood Neuroendocrine Gene Transcript Measurement in Defining Surgical Resection and Residual Disease in Bronchopulmonary Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Filosso

Abstract ID: 297

C41 – Predictive Rates of Survival Based on Ki-67 and Chemotherapy Regimens in Patients with High Grade (HG) Neuroendocrine Tumors (NETs)

Published in 2017 Listed under Clinical, Poster

Hall-Thomas

Abstract ID: 308

pdf Download Poster (183 KB)

C42 – Peri-Procedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases

Published in 2017 Listed under Clinical, Poster

Kwon

Abstract ID: 291

pdf Download Poster (815 KB)

C43 – A Minimally Invasive Approach for the Surgical Management of Small Intestine Neuroendocrine Tumors (SI-NETs)

Published in 2017 Listed under Clinical

Mahuron

Abstract ID: 252

C44 – Chromogranin A is an Inadequate Circulating Biomarker for Bronchopulmonary Neuroendocrine Neoplasia Management

Published in 2017 Listed under Clinical

Malczewska

Abstract ID: 292

C45 – Meta-Analysis with Critical Appraisal of miRNA as a Biomarker in Gastroenteropancreatic Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Malczewska

Abstract ID: 293

C46 – The Failure of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Meta-Analysis

Published in 2017 Listed under Clinical

Malczewska

Abstract ID: 294

C47 – Regional Lymph Node Involvement and Outcomes in Appendiceal Neuroendocrine Tumors: A SEER Database Analysis

Published in 2017 Listed under Clinical, Poster

Mehrvarz-Sarshekeh

Abstract ID: 203

pdf Download Poster (836 KB)

C48 – Impact of Ki67 Re-Assessment at Time of Disease Progression in Patients with Pancreatic Neuroendocrine Neoplasms

Published in 2017 Listed under Clinical

Partelli

Abstract ID: 260

C49 – Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and is Not Age-Dependent

Published in 2017 Listed under Clinical

Partelli

Abstract ID: 268

C50 – Number of Positive Nodes Accurately Predicts Recurrence after Pancreaticoduodenectomy for Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Partelli

Abstract ID: 270

C51 – Relevance of Serum Chromogranin A as Diagnostic and Prognostic Marker for Well-Differentiated Pancreatic Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Pulvirenti

Abstract ID: 265

C52 – Nonfunctional Pancreatic Neuroendocrine Tumors: A Retrospective Review and Early Detection Facilitated by EUS and Novel CORE Biopsy Techniques

Published in 2017 Listed under Clinical, Poster

Sharma

Abstract ID: 220

pdf Download Poster (556 KB)

C53 – The Effects of Peritoneal Carcinomatosis on the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors

Published in 2017 Listed under Clinical

Wang

Abstract ID: 259

C54 – Lobectomy with Mediastinal Nodal Dissection vs. Partial Lobectomy in Patients with Bronchial Carcinoid Tumors

Published in 2017 Listed under Clinical

Westin

Abstract ID: 235

C55 – Does Plasma Neurokinin A Predict Survival in Well-Differentiated Neuroendocrine Tumors (NETs) of the Small Bowel?

Published in 2017 Listed under Clinical, Poster

Woltering, MD, FACS

Abstract ID: 239

pdf Download Poster (76 KB)

C56 – Neuroendocrine Proliferations in Inflammatory Bowel Disease

Published in 2017 Listed under Clinical, Poster

Wong

Abstract ID: 306

pdf Download Poster (29.70 MB)

C57 – Assessment of Disease Aggression in Cystic Pancreatic NET: a CT and Pathology Correlation Study

Published in 2017 Listed under Clinical

Yano

Abstract ID: 202

C58 – Chronic use of Long-acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in patients with Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): An Under-recognized Adverse Effect

Published in 2017 Listed under Clinical, Poster

Saif

pdf Download Poster (1.49 MB)

O01 – Integrating Patient Reported Outcomes (PROs) in Neuroendocrine Tumors (NETs) Care: An Assessment of Neuropsychological and Quality of Life Screening Tools

Published in 2017 Listed under Other

Hallet

Abstract ID: 230

O02 – The Distal Predilection of Small Bowel Neuroendocrine Tumors

Published in 2017 Listed under Other, Poster

Keck

Abstract ID: 211

pdf Download Poster (1.01 MB)

O03 – Blood Neuroendocrine Transcript Analysis for the Diagnosis and Clinical Status Assessment of Bronchopulmonary Neuroendocrine Tumors

Published in 2017 Listed under Other

Modlin

Abstract ID: 296

O04 – Pancreatic Neuroendocrine Tumors: CT Enhancement, but not Histologic Grade, Correlates with Tumor Aggression

Published in 2017 Listed under Other

Yano

Abstract ID: 201

P01 – Predictive Factors of Carcinoid Syndrome (CS) Among Patients with Gastrointestinal Neuroendocrine Tumors (GI NETs)

Published in 2017 Listed under P, Poster

Cai

Abstract ID: 217

pdf Download Poster (534 KB)

P02 – A Novel Form of Familial Multiple Carcinoid Tumors Affecting the Small Intestine, Lung, Pancreas and Colon

Published in 2017 Listed under P

Chitsaz

Abstract ID: 286

P03 – Neuroendocrine Tumors and Obesity: A Targeted Literature Review

Published in 2017 Listed under P

Colby

Abstract ID: 218

P04 – Treatment Response and Clinical Outcomes of Poorly Differentiated (PD) Grade 3 (G3) Gallbladder Neuroendocrine Carcinomas (NEC): A Single Institution Experience

Published in 2017 Listed under P

Corbett

Abstract ID: 283

P05 – Carcinoid Heart Disease in Patients with Bronchopulmonary Carcinoid

Published in 2017 Listed under P

De Jesus

Abstract ID: 275

P06 – Carcinoid Tumors of the Ovary: An Observational Cohort Study of 67 Primary and Metastatic Cases

Published in 2017 Listed under P, Poster

Feingold

Abstract ID: 280

pdf Download Poster (945 KB)

P07 – Association Between Duration of Somatostatin Analogs (SSAs) Use and Quality of Life in Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument

Published in 2017 Listed under P, Poster

Halperin

Abstract ID: 243

pdf Download Poster (354 KB)

P08 – Assessment of the Association Between the Burden of Carcinoid Syndrome Symptoms and the Quality of Life Among Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument

Published in 2017 Listed under P, Poster

Huynh

Abstract ID: 245

pdf Download Poster (282 KB)

P09 – International Patient Survey of Physical, Emotional, and Informational Challenges when Living with Neuroendocrine Tumors: Understanding the Unmet Needs

Published in 2017 Listed under P, Poster

Khan

Abstract ID: 266

pdf Download Poster (417 KB)

P10 – Somatostatin Analog Usage in Neuroendocrine Tumors: A Retrospective Database Analysis

Published in 2017 Listed under P

Klink

Abstract ID: 234

P11 – Evaluation of the Impact of the Burden of Carcinoid Syndrome Symptoms on Quality of Life Among Treated Patients with Carcinoid Syndrome in the U.S. Based on the PROMIS–29 Instrument

Published in 2017 Listed under P, Poster

Neary

Abstract ID: 244

pdf Download Poster (321 KB)

P12 – Ovarian Metastasis from Midgut Neuroendocrine Tumors: Incidence, Clinical Implications, and Management Options—An Update

Published in 2017 Listed under P

Wang

Abstract ID: 258

T01 – Avelumab in Advanced Neuroendocrine Tumours (NET) of Gastroenteropancreatic or Lung Origin

Published in 2017 Listed under Poster, T

Chan

Abstract ID: 295

pdf Download Poster (579 KB)

T02 – A Phase 1 Study of Fosbretabulin in Combination with Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After At Least One Prior Regimen for Metastatic Disease

Published in 2017 Listed under T

Chauhan

Abstract ID: 250